Skip to main content

Table 1 Patient characteristics and available tissues

From: A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients

a. Prostate biopsy cores

Characteristic

Controls (N = 67)

Cases (N = 37)

Age (yrs)

63.66 (8.1, N = 67)

70.9 (9.0, N = 31)

Race

  

Black

3 (4.5%)

1 (2.7%)

Hispanic

0 (0%)

0 (0%)

White

64 (95.5%)

19 (51.4%)

Unknown

0 (0%)

17 (45.9%)

Number cores available

  

1

10 (14.9%)

0 (0%)

2

56 (83.5%)

28 (75.7%)

3

1 (1.5%)

4 (10.8%)

4

0 (0%)

5 (13.5%)

Total

125

88

Number benign cores available

  

1

25 (37.3%)

29 (78.4%)

2

41 (61.2%)

2 (5.4%)

3

0 (0%)

1 (2.7%)

Number abnormal cores available

  

1

17 (25.4%)

7 (18.9%)

2

0 (0%)

3(8.1%)

3

1 (1.5%)

0 (0%)

Number cancer cores available

  

1

0 (0%)

35 (94.6%)

2

0 (0%)

2 (5.4%)

b. Patient characteristics

Patient status

Attribute

Median

Mean

Std Dev

Range

Controls

     
 

Age (n = 67)

63.33

63.66

8.11

49.17-86.08

 

PSA (n = 66)

6.22

7.3

4.651

0.09-23.31

 

Follow Up In Mos. (n = 67)

53

50.46

10.656

19-66

Cases

     
 

Age (n = 31)

72.17

70.77

9.025

52.33-84.33

 

PSA (n = 29)

5.9

6.45

2.28

2.9-12

 

Case Gleason Score (n = 29)

7

7.1

0.938

6-9

 

Core Gleason Score (n = 38)

6

6.53

1.269

4-9

 

% Core Involved (n = 38)

20

23.73

18.995

<1-80